An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity
- 24 May 2006
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 538 (1-3), 168-174
- https://doi.org/10.1016/j.ejphar.2006.03.051
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The Clinical Significance of Cathepsin S Expression in Human AstrocytomasThe American Journal of Pathology, 2003
- The design of potent hydrazones and disulfides as cathepsin S inhibitorsBioorganic & Medicinal Chemistry, 2003
- Cytokines Regulate Proteolysis in Major Histocompatibility Complex Class II–Dependent Antigen Presentation by Dendritic CellsThe Journal of Experimental Medicine, 2001
- Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitorArthritis & Rheumatism, 2001
- The role of lysosomal proteinases in MHC class Il‐mediated antigen processing and presentationImmunological Reviews, 1999
- Cathepsin S Controls the Trafficking and Maturation of Mhc Class II Molecules in Dendritic CellsThe Journal of cell biology, 1999
- Trans vivo analysis of human delayed-type hypersensitivity reactivityHuman Immunology, 1999
- Endosomal proteolysis and MHC class II functionCurrent Opinion in Immunology, 1998
- Lysosomal processing of amyloid precursor protein to Aβ peptides: a distinct role for cathepsin SBiochemical Journal, 1995
- Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?Annals Of The Rheumatic Diseases, 1993